An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the antic...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Fernández, Ariel, Sanguino, Angela, Peng, Zhenghong, Ozturk, Eylem, Chen, Jianping, Crespo, Alejandro, Wulf, Sarah, Shavrin, Aleksander, Qin, Chaoping, Ma, Jianpeng, Trent, Jonathan, Lin, Yvonne, Han, Hee-Dong, Mangala, Lingegowda S., Bankson, James A., Gelovani, Juri, Samarel, Allen, Bornmann, William, Sood, Anil K., Lopez-Berestein, Gabriel
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society for Clinical Investigation 2007
विषय:
Technical Advance
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC2104494/
https://ncbi.nlm.nih.gov/pubmed/18060038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI32373
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन